Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:30:22.464Z.
Calculation as of: 2026-10-06T13:30:22.464Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5c9508078213b28dfeff6809371853141f28b2786ea2d18fc4f82dd6840af9a4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$9.88M
PS Ratio
5.77
TTM Avg
39.64
3Y Avg
50.81
5Y Avg
50.81
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Advanced Biomed Inc. Common Stock (ADVB) | $8.83M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.91M | 0.35 | 0.20 | 0.21 | 0.26 |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.42M | N/A | 33.16 | 27.80 | 27.84 |
| HeartSciences Inc. (HSCS)vs › | $8.18M | N/A | 795.02 | 643.34 | 689.54 |
| GT Biopharma, Inc. (GTBP)vs › | $7.96M | N/A | 851.62 | 851.62 | 851.62 |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.75M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.89M | N/A | N/A | N/A | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.88M | 5.77 | 39.64 | 50.81 | 50.81 |
| Ainos, Inc. (AIMD)vs › | $9.94M | 731.04 | 337.84 | 351.63 | 923.89 |
| Longeveron Inc. (LGVN)vs › | $7.61M | 6.41 | 12.07 | 14.45 | 39.63 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-08 |
| Q1 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-19 |
| Q2 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-13 |
| Q3 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
